DIAMICRON MR 30 MG
GLICLAZIDE : 30 MG · DIN 02242987 · SERVIER CANADA INC
Health Canada status: MARKETED
What is DIAMICRON MR?
DIAMICRON MR 30 MG contains GLICLAZIDE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02242987, held by SERVIER CANADA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Apr-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIAMICRON MR used for?
DIAMICRON® MR (gliclazide modified-release tablets 30 and 60 mg) is indicated for: • Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is DIAMICRON MR called?
The same molecule, GLICLAZIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DIASTAB | Latin | Morocco |
| Gliclazide Sandoz MR | Latin | Australia |
| Pharmacor Gliclazide MR | Latin | Australia |
| APO-Gliclazide MR | Latin | Australia, Bahrain |
| GLYCEMAT | Latin | Morocco |
| Adco-Glucomed | Latin | South Africa |
| APX-Gliclazide | Latin | Australia |
| ARX-Gliclazide MR | Latin | Australia |
| DIAMICRON | Latin | Morocco |
| DIAMICRON LM | Latin | Morocco |
| Gliclazide Lupin MR | Latin | Australia |
| Gliclazide MR Viatris | Latin | Australia |
| GLYAZID | Latin | Morocco |
| Glyvanza | Latin | Saudi Arabia |
| MICROZIDE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02242987 |
|---|---|
| Brand name | DIAMICRON MR |
| Generic / active ingredient | GLICLAZIDE : 30 MG |
| Manufacturer | SERVIER CANADA INC |
| Strength | 30 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BB09 GLICLAZIDE |
| AHFS class | 68:20.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Apr-2001 |
| Original market date | 2001-04-04 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02242987 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242987 |
| Brand name | DIAMICRON MR |
| Active ingredient / INN | GLICLAZIDE : 30 MG |
| ATC code | A10BB09 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10 |
| AHFS class | 68:20.20 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SERVIER CANADA INC |
How is it stored and handled?
null
How is it supplied?
DIAMICRON® MR 30 mg is available in boxes of 60 tablets (containing two heat-sealed blister strips of 30 tablets) and in bottles of 100 tablets. DIAMICRON® MR 60 mg is supplied in boxes of 30 or 60 tablets (containing two or four heat-sealed blister strips of 15 tablets) and in bottles of 100 tablets.
Which pack is which?
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | DIAMICRON® MR 30 mg is available in boxes of 60 tablets (containing two heat-sealed blister strips of 30 tablets) and in bottles of 100 tablets. DIAMICRON® MR 60 mg is supplied in boxes of 30 or 60 tablets (containing two or four heat-sealed blister strips of 15 tablets) and in bottles of 100 tablets. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Is GLICLAZIDE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A10BB09 GLICLAZIDE. 16 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02483300 |
| AG-GLICLAZIDE MR | 60 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02483319 |
| APO-GLICLAZIDE | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02245247 |
| APO-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02297795 |
| APO-GLICLAZIDE MR | 60 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02407124 |
| DIAMICRON MR | 60 MG | TABLET (EXTENDED-RELEASE) | SERVIER CANADA INC | MARKETED | DIN 02356422 |
| GLICLAZIDE | 80 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02287072 |
| JAMP GLICLAZIDE-MR | 30 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02429764 |
| JAMP GLICLAZIDE-MR | 60 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02429772 |
| MINT-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | MINT PHARMACEUTICALS INC | MARKETED | DIN 02423286 |
Who else supplies GLICLAZIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLICLAZIDE appears in 245 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does GLICLAZIDE cost around the world?
GLICLAZIDE is listed on 9 national price registers Nexara tracks, across 146 pack listings published on 8 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 13 | 39 | 02 Sep 2026 |
| South Africa | single exit price | 31 | 34 | 01 Sep 2026 |
| Australia | ex-manufacturer | 10 | 24 | 08 Sep 2026 |
| Morocco | PPV (public price) | 8 | 19 | 05 Sep 2026 |
| Saudi Arabia | public | 12 | 17 | 01 Sep 2026 |
| United Arab Emirates | public | 4 | 4 | 31 Aug 2026 |
| Bahrain | retail (max) | 3 | 3 | 01 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.